Cantor Fitzgerald Analysts Cut Earnings Estimates for PTCT

PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) - Cantor Fitzgerald dropped their FY2025 EPS estimates for PTC Therapeutics in a report released on Monday, February 3rd. Cantor Fitzgerald analyst K. Kluska now anticipates that the biopharmaceutical company will post earnings per share of ($3.26) for the year, down from their prior forecast of ($2.84). Cantor Fitzgerald currently has a "Overweight" rating and a $113.00 price target on the stock. The consensus estimate for PTC Therapeutics' current full-year earnings is ($4.56) per share.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($1.39) EPS for the quarter, topping analysts' consensus estimates of ($1.54) by $0.15. The firm had revenue of $196.79 million during the quarter, compared to analyst estimates of $173.51 million. During the same quarter in the previous year, the business earned ($1.76) earnings per share.

Other research analysts have also issued reports about the company. Citigroup raised their price target on PTC Therapeutics from $26.00 to $32.00 and gave the stock a "sell" rating in a research report on Wednesday, December 4th. The Goldman Sachs Group increased their price target on shares of PTC Therapeutics from $32.00 to $42.00 and gave the company a "sell" rating in a research report on Wednesday, December 4th. Royal Bank of Canada upgraded shares of PTC Therapeutics from a "sector perform" rating to an "outperform" rating and boosted their price objective for the company from $39.00 to $63.00 in a report on Tuesday, December 3rd. Robert W. Baird upped their target price on shares of PTC Therapeutics from $52.00 to $70.00 and gave the company an "outperform" rating in a research note on Tuesday, December 3rd. Finally, Wells Fargo & Company lifted their price target on shares of PTC Therapeutics from $56.00 to $68.00 and gave the stock an "overweight" rating in a research report on Tuesday, November 26th. Three research analysts have rated the stock with a sell rating, three have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $57.85.

PTC Therapeutics Stock Down 0.6 %

NASDAQ PTCT traded down $0.32 during trading hours on Wednesday, hitting $49.47. The company's stock had a trading volume of 425,361 shares, compared to its average volume of 727,904. PTC Therapeutics has a twelve month low of $23.58 and a twelve month high of $54.16. The firm has a market capitalization of $3.82 billion, a P/E ratio of -8.33 and a beta of 0.62. The stock has a fifty day moving average of $46.44 and a 200 day moving average of $40.30.

Insider Activity

In other PTC Therapeutics news, CAO Christine Marie Utter sold 17,800 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $51.77, for a total value of $921,506.00. Following the completion of the sale, the chief accounting officer now owns 52,428 shares in the company, valued at approximately $2,714,197.56. This trade represents a 25.35 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Lee Scott Golden sold 810 shares of PTC Therapeutics stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $45.34, for a total value of $36,725.40. Following the sale, the executive vice president now owns 79,849 shares in the company, valued at $3,620,353.66. This trade represents a 1.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 211,737 shares of company stock worth $10,920,687. Company insiders own 5.50% of the company's stock.

Hedge Funds Weigh In On PTC Therapeutics

Several institutional investors have recently bought and sold shares of the company. GC Wealth Management RIA LLC purchased a new stake in PTC Therapeutics in the 4th quarter worth about $363,000. SPX Gestao de Recursos Ltda purchased a new stake in shares of PTC Therapeutics during the 4th quarter valued at approximately $1,128,000. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in PTC Therapeutics by 22.4% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,863 shares of the biopharmaceutical company's stock worth $851,000 after buying an additional 3,450 shares during the period. Raymond James Financial Inc. purchased a new position in PTC Therapeutics in the 4th quarter valued at approximately $2,200,000. Finally, Arizona State Retirement System boosted its stake in PTC Therapeutics by 1.1% in the 4th quarter. Arizona State Retirement System now owns 20,095 shares of the biopharmaceutical company's stock worth $907,000 after purchasing an additional 219 shares during the period.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.